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ABSTRACT
Roles for SOX9 have been extensively studied in de-
velopment and particular emphasis has been placed
on SOX9 roles in cell lineage determination in a num-
ber of discrete tissues. Aberrant expression of SOX9
in many cancers, including colorectal cancer, sug-
gests roles in these diseases as well and recent
studies have suggested tissue- and context-specific
roles of SOX9. Our genome wide approach by chro-
matin immunoprecipitation sequencing (ChIP-seq) in
human colorectal cancer cells identified a number
of physiological targets of SOX9, including ubiqui-
tously expressed cell cycle regulatory genes, such
as CCNB1 and CCNB2, CDK1, and TOP2A. These
novel high affinity-SOX9 binding peaks precisely
overlapped with binding sites for histone-fold NF-Y
transcription factor. Furthermore, our data showed
that SOX9 is recruited by NF-Y to these promoters of
cell cycle regulatory genes and that SOX9 is critical
for the full function of NF-Y in activation of the cell
cycle genes. Mutagenesis analysis and in vitro bind-
ing assays provided additional evidence to show that
SOX9 affinity is through NF-Y and that SOX9 DNA
binding domain is not necessary for SOX9 affinity to
those target genes. Collectively, our results reveal
possibly a context-dependent, non-classical regula-
tory role for SOX9.
INTRODUCTION
SOX proteins, high-mobility group, (HMG)-box transcrip-
tion factors, play crucial roles in embryonic and adult di-
verse tissues; these include maintenance of stem cell prop-
erties, lineage specification and terminal differentiation in
a cell-type and tissue-specific manner. In the intestinal ep-
ithelium, SOX9 is expressed in the stem/progenitor cells, as
well as in the nuclei of terminally differentiated Paneth cells
of the small intestinal crypts and tuft cells in the villi and it
plays a crucial role in Paneth cell differentiation (1,2). Aber-
rant expression of SOX9 in some human cancers, including
colorectal cancer and in Apc(min/+) mouse intestinal ade-
nomas suggest roles of SOX9 in colorectal cancer and to de-
lineate the roles of SOX9 in colorectal cancer has been a fo-
cus of some recent studies. However, there have been reports
of opposing SOX9 functions, promoting and suppressing of
proliferation, which suggest diverse, context-specific func-
tions of SOX9 in proliferation. This has been shown in
both developmental and cancer contexts. For instance, in
normal chondrocytic CFK2 cells and M12 prostate tumor
cells, SOX9 overexpression resulted in decreased prolifera-
tion rate and cell cycle arrest in G0/G1 (3,4), while Sox9
knockdown in rat mesenchymal stem cells (MSCs) resulted
in a marked decrease in proliferation rate through delayed
S-phase progression and increased nuclear localization of
p21 (5). Furthermore, differential roles of SOX9 have been
demonstrated in normal intestinal epithelium; low SOX9
expression was associated with enhanced proliferative ca-
pacity and high SOX9 expression suppressed proliferation
(6). Another study showed that SOX9 expression facilitated
growth and proliferation of colorectal cancer cells, whereas
inactivation reduced tumorigenicity (7).
To gain insight into SOX9-mediated transcriptional reg-
ulation in colorectal cancer cells, we first attempted to
identify its physiological targets on a genome-scale us-
ing chromatin immunoprecipitation (ChIP) followed by se-
quencing (ChIP-seq) in human colorectal cancer cells. Our
ChIP-seq analysis revealed a large number of SOX9 tran-
scriptional targets in diverse pathways. Interestingly, mo-
tif analysis revealed CCAAT, a binding sequence for the
heterotrimeric NF-Y transcription factor, as a preferred
*To whom correspondence should be addressed. Tel: +1 832 824 8231; Fax: +1 832 825 1165; Email: moriakiy@bcm.edu
C© The Author(s) 2015. Published by Oxford University Press on behalf of Nucleic Acids Research.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which
permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
6258 Nucleic Acids Research, 2015, Vol. 43, No. 13
SOX9 binding sequence, in addition to the previously iden-
tified classical consensus motif, A/TA/TCAAA/TG. Statisti-
cal analysis of the ChIP-seq data further revealed that many
physiological SOX9 targets through the CCAAT motif are
on cell cycle regulatory genes, including the promoters of
well-characterized G2/M-specific genes, such as cyclin B1
(CCNB1) (8), cyclin B2 (CCNB2) (9), cyclin dependent ki-
nase 1 (CDK1) (10) and topoisomerase II  (TOP2A) (11).
The current study revealed that, in colorectal cancer cells,
SOX9 is recruited by NF-Y to the target genes and inter-
acts with NF-Y on CCAAT promoter sequences and that
SOX9 is necessary for the function of NF-Y in activating
expression of some cell-cycle regulatory gene expressions.
MATERIALS AND METHODS
Cell culture
HT29 and HCT116 cells, both human colon adenocarci-
noma cell lines, were purchased from ATCC and cultured
in McCoy’s 5A Medium (ATCC, Manassas, VA, USA) with
10% FCS (Lonza, Verviers, Belgium) at 37◦C in a 5% CO2
atmosphere.
ChIP-seq
ChIP assays were performed as previously described (12)
using an anti-SOX9 antibody (Millipore, Billerica, MA,
USA) and an anti-NF-YA antibody (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA). ChIP-seq experiment was
performed from one biological replicate. SOX9 ChIP was
subjected to sequencing on Illumina HiSeq 2000. Sequenc-
ing of input DNA served as control for peak calling and
was also used to generate a control visualization track. Se-
quences (50-nt reads, single end) were aligned to the hu-
man genome (hg19) using BWA algorithm. Only uniquely
mapping reads were used in the analysis and duplicate reads
were removed. Because the number of final alignments ob-
tained was >2× more for the Input data than for the ChIP
data, the Input file was adjusted to the ChIP alignment
number by randomly removing excess alignments (down-
sampling). Aligns were extended in silico at their 3′- ends to
a length of 150 bp, which is the average genomic fragment
length in the size-selected library and assigned to 32-nt bins
along the genome. The resulting histograms (genomic ‘sig-
nal maps’) were stored in BAR files. Peak locations were de-
termined using the MACS algorithm (v1.3.7.1) with a cut-
off P-value = 1e-7. In an attempt to optimize peak calling
and to reduce the calling of false peaks, the mfold parame-
ter was set to 16 (default 32) and the P-value cut-off was set
to 1e-7. Signal maps and peak locations were used as input
data to Active Motif ’s (Carlsbad, CA, USA) proprietary
analysis program, which was used to create Excel spread-
sheets containing detailed information on sample compari-
son, peak metrics, peak locations and gene annotations.
Bioinformatics analysis
The top 1200 peak sequences (i.e. those with the high-
est fragment density, from −25 to +25 bp relative to the
fragment density peak) were analyzed by MEME (13,14),
varying the max width and palindrome requirement set-
tings. Identified motifs were further analyzed with TOM-
TOM (15) and the presence of SOX9-consensus-like mo-
tifs in the 17 847 MACS peak sequences was examined
using FIMO (16). Both TOMTOM and FIMO were run
with default settings. Human Three publicly accessible NF-
YA ChIP-seq data were obtained for bioinformatics anal-
ysis. The Encyclopedia of DNA Elements (ENCODE)
project was used for genome wide comparison analysis and
three data sets from UCSC website (HeLa-S3, Accession
number: wgEncodeEH002066; GM12878, Accession num-
ber: wgEncodeEH002064; K562, Accession number: wgEn-
codeEH002021) were used to confirm the alignments of
the peaks on key genes. Peak locations were intersected
with gene features obtained from the RefSeq database using
BEDTools (17) and overlap counts were determined using
standard UNIX commands. Tag counts in regions contain-
ing either a SOX9 peak or a SOX9 peak overlapping with
an NF-YA peak were extracted from the signal maps using
the Active Motif pipeline mentioned above and plotted in
R (18). Pathway analysis was carried out through the use
of QIAGEN’s Ingenuity R© Pathway Analysis (IPA R©, QIA-
GEN Redwood City).
ChIP-qPCR
ChIP was performed using the ChIP-IT Express Kit (Ac-
tive Motif) according to the manufacturer’s instructions,
with minor modifications. Cells were cross-linked with 1%
formaldehyde, disrupted with a Dounce homogenizer and
the chromatin was isolated. The lysates were sonicated
to shear the DNA to an average length of 300–600 bp.
Chromatin was immunoprecipitated using an anti-SOX9
(Millipore) antibody or anti-NF-YA antibody (Santa Cruz
Biotechnology). ChIP DNAs were purified and ChIP en-
richment was quantified by quantitative PCR (qPCR). Fold
enrichment was determined by the percent input method.
Several key SOX9 and NF-YA peaks identified with ChIP-
seq assay were validated on multiple biological samples by
qPCR, minimum biological triplicates. Standard deviation
(SD) was determined using triplicate measurements. PCR
primers were designed to amplify regions spanning the cen-
ter of peaks obtained from ChIP-seq data and a control
primer pair was designed to amplify a region in a gene desert
on chromosome 12. Primers used for ChIP-qPCR are listed
in Supplementary Table S1.
RNA extraction and RT-PCR analysis
Total RNA was extracted using Trizol reagent (Life
Technologies, Gaithersburg, MD, USA) and treated with
RNase-free DNase (Roche, Indianapolis, IN, USA) accord-
ing to manufacturer’s instructions. One microgram of to-
tal RNA was converted to cDNA using the Transcriptor
First Strand cDNA Synthesis Kit (Roche). Real time qRT-
PCR analyses were performed using FastStar Universal
SYBR Green Master Mix (Roche) and amplified on the Ap-
plied Biosystems 7900HT instrument. Primers used were:
CCNB1 (forward, 5′- TACCTATGCTGGTGCCAGTG-
3′ and reverse, 5′- CAGATGTTTCCATTGGGCTT-3′),
CDK1 (forward, 5′-AAGCCGGGATCTACCATACC -
3′ and reverse, 5′-CATGGCTACCACTTGACCTGT -3′).
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Relative levels of gene expression were analyzed using the
2Ct method.
Plasmids and transfection
FLAG-tagged wild-type and HMG-deleted SOX9 con-
structs were generously provided by Dr Benoit de Crom-
brugghe (the University of Texas, M. D. Anderson Cancer
Center). The FLAG-tagged SOX9–303C construct was
derived from the FLAG-tagged wild-type SOX9 construct
using primers spanning the sequence encoding the first 303
amino acids of human SOX9. FLAG-SOX9HMG-NLS
construct was generated by adding an extra nuclear local-
ization sequence, PKKKRKV, encoded by the sequence
CCCAAGAAGAAGCGGAAGGTG, to the C terminus
of FLAG-SOX9HMG. The fragment of 0.8 kb human
TOP2A promoter was cloned into a pGL3 luciferase vector
(Promega, Madison, WI, USA). Mutant human TOP2A
promoter was made by 1 bp mutation in the putative SOX9
enriched site (−106 to −102 bp upstream of TSS) using the
QuickChange Site-Directed Mutagenesis Kit (Stratagene,
La Jolla, CA, USA). 1 × 106 HCT116 cells were transfected
with 10 g of plasmids using X-tremeGENE HP DNA
Transfection Reagent (Roche) following the manufacturer’s
instructions. Cells were collected for the following assays 48
h after transfection.
Knockdown of SOX9 and NFYA
Short interfering RNA (SiRNA)-mediated SOX9 knock-
down was performed as previously described using SOX9
siRNA (19). For NFYA knockdown, cells were transfected
with 75 nM siRNA targeting NFYA or control siRNA
(Thermo Scientific, Waltham, MA, USA) using Dharma-
FECT 4 siRNA Transfection Reagent (GE Healthcare,
Chalfont St Giles, UK). Cells were harvested 48 h post-
transfection for further analysis.
Immunofluorescence and proximity ligation assay (PLA)
HCT116 cells were transfected with FLAG-SOX9HMG,
FLAG-SOX9HMG-NLS or FLAG-SOX9–303 C plas-
mids. Forty-eight hours later, cells were fixed with 4%
paraformaldehyde for 10 min at room temperature and per-
meabilized with 0.5% Triton X-100 followed by blocking at
37◦C for 30 min. Cells were then incubated with primary an-
tibody against FLAG (SCBT), followed by incubation with
the Alexa Fluor 555 goat anti-rabbit secondary antibodies
(Life Technologies). The cells were mounted in SlowFade R©
Gold Antifade Reagent with DAPI (Life Technologies) and
the red fluorescence was visualized under a fluorescence
microscope (Nikon). The interaction between SOX9 and
NF-YA was demonstrated by in situ proximity ligation as-
say (PLA) using a Duolink in situ red starter kit (Sigma-
Aldrich, Louis, MO, USA) according to the manufacturer’s
instructions. Briefly, HCT116 and HT29 cells were fixed in
4% paraformaldehyde for 10 min at room temperature and
permeabilized with 0.5% Triton X-100 followed by blocking
at 37◦C for 30 min. Cells were then incubated with primary
antibodies against SOX9 (1:500), NF-YA (1:500) or con-
trol mouse IgG (1:500), followed by washing and incubation
with the secondary antibodies conjugated to PLA probes.
After ligation and amplification, the red fluorescence indi-
cating the interaction between SOX9 and NF-YA was visu-
alized under a fluorescence microscope (Nikon).
Western blotting and immunoprecipitation
HCT116 cells and HT-29 cells were lysed in modified
RIPA buffer (1% Nonidet P-40, 0.1% sodium deoxycholate,
150 mm NaCl and 1 mm ethylenediaminetetraacetic acid
(EDTA) in 50 mm Tris–HCl, pH 7.5) supplemented with
1× protease inhibitor mixture (Sigma-Aldrich). Solubilized
proteins were separated by electrophoresis through 10%
Tris-glycine gels and transferred onto PVDF membranes.
Primary antibodies used for western analysis were rab-
bit polyclonal anti-SOX9 (Millipore), mouse monoclonal
anti-NF-YA (Santa Cruz Biotechnology) and mouse mono-
clonal anti--actin (Santa Cruz Biotechnology). Secondary
antibodies used were horseradish peroxidase-conjugated
goat anti-mouse and goat anti-rabbit (Santa Cruz Biotech-
nology). For co-immunoprecipitation, cells were lysed in
RIPA buffer and immunoprecipitated overnight at 4◦C with
2 g antibody and 20 l protein-A/G agarose beads (Santa
Cruz Biotechnology). Bead-bound complexes were washed,
eluted and visualized by western blotting.
Pull-down assays
Nuclear extracts were obtained from HCT116 cells. A
total of 100 g of nuclear proteins were mixed with 2
g of biotin-labeled double-stranded TOP2A oligos (wild-
type TOP2A oligo: 5′ biotin-TCCCGCCTCCCTAACC
TGATTGGTTTATTCAAACAAACC; mutated TOP2A
oligo: 5′ biotin-TCCCGCCTCCCTAACCTGTTTGGT
TTATTCAAACAAACC) and 5 g of polyIC in 1× bind-
ing buffer (5× binding buffer: 75 mM Hepes PH7.9, 400
mM NaCl, 75 mM KCl, 0.1 mM EDTA, 5 mM dithiothre-
itol (DTT), 5 mM phenylmethanesulfonylfluoride (PMSF),
and 15% glycerol) for 60 min on ice. Then 40 l of mag-
netic beads (Dynabead M-280 streptavidin) were added into
the complexes of reactions followed by rotation at 4◦C for
30 min. Beads were washed three times with 500 l of 1×
binding buffer. The associated proteins to the biotin-labeled
oligos were detected by western blot using either an anti-
NF-YA or an anti-SOX9 antibody.
Electrophoretic mobility shift assay (EMSA)
Electrophoretic mobility shift assay (EMSA) was per-
formed with double-stranded, biotin-labeled oligonu-
cleotides using the Gelshift Chemiluminescent EMSA Kit
(Active Motif) according to the manufacturer’s instruction.
Recombinant human SOX9 protein (OriGene) and/or
unlabeled oligonucleotides (cold probes) were added to
the biotin-labeled oligonucleotides. The binding reactions
were resolved on a non-denaturing polyacrylamide gel and
transferred to a nylon membrane, followed by crosslink
using UV cross-linker (Stratagene). The membrane was
incubated with HRP conjugated streptavidin. The protein–
DNA bindings were detected using SuperSignal West
Femto Chemiluminescent Substrate (Thermo Scientific).
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Luciferase reporter activity assays
HCT116 cells were plated in 24-well plate at a density of
4 × 104 cells/well and transfected 24 h later with 500 ng
of pGL3 empty vector, 500 ng of human TOP2A wild-type
or mutant TOP2A plasmids, together with 2 ng of the TK
standardization vector used to normalize the transfection
efficiency. Luciferase activity was measured 48 h after the
transfection using a Dual Luciferase Reporter Assay system
(Promega).
Statistical analysis
Results are expressed as mean ± SD. Differences between
two groups were analyzed using an unpaired Student’s t-
test and a P < 0.05 was considered significant. (* P < 0.05;
** P < 0.01 and *** P < 0.001).
RESULTS
Identification of SOX9 interaction sites in the genome of hu-
man colorectal cancer cells
Aberrant expression of SOX9 in various cancers suggests a
role of SOX9 in these diseases. The current study aimed to
give insight into roles of SOX9 as a transcription factor by
identifying SOX9 target genes in the genome of human col-
orectal cancer cells. We first carried out ChIP-seq analysis
using an antibody specific to SOX9 in HT-29 cells, which ex-
press endogenous SOX9 at a considerably high level. MACS
peak finding (20) using the default cut-off of P-value = 1e-
7 identified 17 847 peaks of SOX9 binding enrichment. The
empirical false discovery rate, calculated by MACS with a
ChIP input sample swap, was 0.01%. For each peak, the dis-
tance to RefSeq transcription start site(s) (TSSs) was de-
termined. Figure 1A (left) shows that SOX9 binding sites
have a strong preference for TSSs (distance = 0). Figure 1A
(right) demonstrates, at higher resolution, that the major-
ity of SOX9 binding sites are located just upstream of the
TSS. We also annotated the MACS SOX9 peak locations
to RefSeq gene features. As a control, an equal number (17
847) of random genomic locations (generated by sampling
input tag locations) were annotated in the same way (Fig-
ure 1B). The results demonstrated that SOX9 binding sites
are significantly enriched in proximal promoters (within 1
kb upstream of TSS; 25% versus 2%) and 5′-UTRs (10%
versus 0.2%), whereas they are underrepresented in intronic
and intergenic regions relative to random distribution, de-
spite the high absolute percentages of peaks in these fea-
tures. Repetitive sequences are known to be many transcrip-
tion factors binding sites, however, the ‘depletion’ of re-
peat masked regions in SOX9 peaks was observed (nega-
tive log2 values). This indicated that SOX9 peaks are actu-
ally underrepresented in repeat masked regions (2474 ver-
sus 7820), while simple repeats have close to random occur-
rence (311 versus 298 hits). It is probably the case that the
under-representation of SOX9 peaks in repeat masked re-
gions cannot simply be explained by a difficulty of mapping
reads to such regions, as the random peak control was gen-
erated based on a random sampling of mapped input reads;
in addition, the majority of 50-nt reads are readily mapped
to unique locations even in repeat masked regions (Supple-
mentary Figure S1). The data shown in Figure 1A and B
thus suggest that in colorectal cancer cells, SOX9 is likely
to bind mainly to the proximal promoters of target genes
and to some extent through 5′ UTR regions. This is consis-
tent with previous reports by others, including SOX9 ChIP-
on-chip analysis of chondrocytes (21) and embryonic go-
nads (22) and SOX9 ChIP-seq analysis of hair follicle stem
cells (23). Several previous studies have identified the se-
quence A/TA/TCAAA/TG as the canonical consensus mo-
tif for SOX9 (21,24). To confirm whether SOX9 also binds
to DNA through this motif in colorectal cancer cells, we
used the motif discovery tool MEME. The top 1200 peak se-
quences (50 bp; ±25 bp relative to summits) were submitted
to MEME using different parameters. The three main mo-
tifs identified are shown in Figure 1C and are referred to as
Motif 1, 2 and 3 throughout in this study. Motif 2 is a perfect
match to the classical SOX9 consensus sequence. Motif 3 is
an inverted repeat of the 7-bp core consensus sequence sep-
arated by 4 bp. This dimeric binding site has been reported
to be required for SOX9 dimerization to regulate gene ex-
pression in chondrogenesis (25). To our surprise, Motif 1,
which has not previously been reported as a SOX9 bind-
ing motif, was the most significant motif in all runs (unless
searching for palindromes only), with even relatively higher
affinity for SOX9, as shown by the number of tags compared
to Motif 2 and/or 3 (Figure 1D).
SOX9 binding sites overlap NF-YA sites in genome of human
colorectal cancer cells
TOMTOM analysis (15) further demonstrated that Mo-
tif 1 sequence contained the core DNA-binding element
CCAAT, flanked by 5′ AG and 3′ CA/GG nucleotides se-
quence, which are identical to the preferred NF-YA binding
motif obtained from the JASPAR CORE database (E-value
of 1.7e-11) (Figure 2A). The NF-YA ChIP-seq data from
ENCODE (Accession number: ENCSR000EGR; k562, hu-
man leukemia cells) contained 7647 peaks, of which 2564
overlapped with our SOX9 ChIP-seq peaks. NF-YA is a
subunit of the heterotrimeric NF-Y transcription factor and
therefore NF-YA ChIP-seq peaks represent binding sites
for NF-Y. This was confirmed by NF-YB ChIP-seq, peaks
of which were identical to those of NF-YA (26). To visual-
ize the correlation between the SOX9 and NF-Y ChIP-seq
data, we determined the number of tags in the NF-YA ChIP
for the genomic regions corresponding to all of the 17 847
SOX9 peaks, regardless of whether they overlapped with a
called NF-Y peak or not. Note that genomic locations that
had only a NF-YA peak but no SOX9 peak were excluded
from the analysis. SOX9 peaks were further annotated with
MEME Motif 1 and Motif 2 and/or 3 using the FIMO
software (16). The scatter plot in Figure 2B represents the
SOX9 peak tag counts versus the NF-YA data tag counts
for the 17 847 SOX9 peaks, which are color-coded depend-
ing on the presence or absence of Motifs 1 (NF-Y consen-
sus) and Motifs 2/3 (SOX9 consensus). Whereas the data
points broadly scatter, the plot clearly demonstrates that
the SOX9 peaks with Motif 1 also have higher NF-YA peak
metrics (green and red), whereas SOX9 peaks without Mo-
tif 1 (blue and black) have low NF-YA peak metrics. Lin-
ear regression lines confirm the higher correlation between
SOX9 and NF-YA peak metrics with Motif 1. Among the
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Figure 1. ChIP-seq analysis of SOX9 binding sites in HT29 cells. (A) Distribution of SOX9 binding sites relative to nearest TSSs. Histograms were generated
from the putative SOX9 binding regions. The left plot (50-bp bins) shows that SOX9- binding sites are enriched symmetrically around TSSs. The right plot
(20-bp bins) shows the preferential location between 0 and −100 bp upstream of TSSs. The x-axes represent relative distance (bp) from the TSS. The y-axes
represent the frequency of peaks in the whole genome. (B) Distribution of SOX9 binding site location relative to RefSeq genes. Locations of binding sites
are divided into distal promoter (−1 to −3 kb upstream of TSS), proximal promoter (−1 to 0 kb), 5′ UTR, exon, intron, 3′ UTR, proximal downstream
(0–1 kb downstream of TSS), distal downstream (1 to 3 kb downstream of TSS) and distal intergenic (>3 kb from genes). (C) Motif analysis from SOX9
ChIP-seq. With identification of statistically over-represented sequences present in ChIP-seq binding loci. A denovo putative binding motif was denoted
Motif 1, in addition to previously identified consensus motifs, Motif 2 and 3. (D) Comparison of tag counts of Motif 1, 2 and 3 genes are demonstrated by
the frequency distribution. The red box indicates genes with more than 300 tags.
SOX9 peaks without Motif 1 (blue and black), the presence
of the SOX9-consensus (Motif 2/3; blue) has only a mini-
mal effect on the number of SOX9 tags, whereas overlapping
SOX9 and NF-Y peaks with Motif 1 were greatly enriched
in the promoter region (75% within 3000 bp of TSS), leav-
ing only 25% located outside promoter regions, including
in distal enhancers. Taken together, the results of our sta-
tistical analysis of promoter sites enriched for SOX9 and
NF-YA strongly suggest that both proteins likely bind to
the same genomic sites.
We then investigated individual NF-Y target genes in the
light of suggested cooperation between SOX9 and NF-YA.
TOP2A, CCNB1, CCNB2 and CDK1 are all well charac-
terized NF-Y transcriptional targets through CCAAT mo-
tifs. Alignment of SOX9 and NF-YA ChIP-seq peaks re-
vealed that the peaks overlapped precisely in the proximal
promoters of TOP2A, CCNB1 (Figure 2C, left), CCNB2
and CDK1 (Supplementary Figure S2). Most other motif
1 genes also showed overlapping SOX9 and NF-YA peak
sequences (data not shown). Note that Motif 2 genes (rep-
resented by USP15 and MTCH1) or Motif 3 genes (repre-
sented by SASH1 and CDCA7L) had SOX9 peaks, but not
NF-YA peaks (Figure 2C).
To confirm that NF-YA binding sites are conserved
among different cell types, we aligned NF-YA binding
peaks on the representative genes, including CCNB1,
CDK1 and TOP2A, using three publicly accessible NF-YA
ChIP-seq data from UCSC website (HeLa-S3, Accession
number: wgEncodeEH002066; GM12878, Accession num-
ber: wgEncodeEH002064; K562, Accession number: wgEn-
codeEH002021). A total of 72 out of randomly selected 100
SOX9 peaks in the proximal promoters had precisely over-
lapping peaks in all three NF-YA ChIP-seq, indicating con-
served binding sites of NF-YA on those target genes. Three
representative peak alignments are shown in Supplemen-
tary Figure S3. We verified randomly selected 15 peaks by
NF-YA ChIP-qPCR in HT-29 cells (Supplementary Figure
6262 Nucleic Acids Research, 2015, Vol. 43, No. 13














































Genes with Motif 3 
C 



















Tag counts (SOX9 data) 
Scatter Plot (SOX9 and NF-YA ChIP-Seq Data) 
Figure 2. SOX9 and NF-Y co-occupy many target genes. (A) SOX9 and NF-YA share high homology of Motif 1 sequences identified by TOMTOM
analysis. (B) Scatter plot of SOX9 and NF-YA peaks containing different combinations of Motif 1 and/or Motif 2–3. Different colors of dots represent
genes with following Motifs: Motif1 only (green), Motif 1 with Motif 2 and/or Motif 3 (red), no Motifs 1, 2 or 3 (blue) and no Motif 1 but Motif 2
and/or Motif 3 (black). X- and y-axes represent number of tags for NF-YA and SOX9 peaks, respectively. (C) Representative readouts of peaks from
SOX9 ChIP-seq (red), NF-YA ChIP-seq (blue) and an input control (black) for indicated genes. Peaks from SOX9 and NF-YA ChIP-seq analyses overlap
only on Motif 1 genes.
S4). The results suggested that the rest of NF-YA peaks ob-
tained from other cells can also be expected in HT29 cells.
The peaks obtained by ChIP-seq and used for the mo-
tif alignment were confirmed by ChIP-qPCR with anti-
SOX9 and anti-NF-YA antibodies in separate ChIP anal-
ysis of HT29 cells (Supplementary Figure S5A and S5B)
and HCT116 cells (data not shown), which validated the
ChIP-Seq data for regions highly enriched for SOX9 and
NF-YA binding and confirmed that the findings were con-
sistent in two colorectal cancer cell lines. These experiments
confirmed that sites highly enriched in SOX9 binding over-
lap the NF-YA binding sites around the TSSs (within 500
bp of TSSs) of TOP2A, CCNB1, CCNB2 and CDK1 in col-
orectal cancer cells. In order to further confirm that SOX9
peaks are specific to some target sites and not to all of NF-
YA binding sites, we verified by SOX9 ChIP-qPCR as well
as NF-YA ChIP-qPCR in both HT-29 cells and HCT116
that only NF-YA has high binding affinity to some of its
target genes, such as the promoter region of LRIF1, but not
SOX9 (Supplementary Figure S6A and S6B). This is addi-
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tional evidence that eliminates the possibility that the over-
lapping peaks of SOX9 and NF-YA may have simply re-
flected their protein to protein affinity or the affinity of anti-
SOX9 antibody to NF-Y. Pathway analysis using IPA (Qi-
agen, Hilden, Germany) suggested that most of the SOX9
target genes related to cell cycle regulation were unique to
Motif 1 genes, whereas genes involved in development and
bone morphologic protein signaling were identified as hav-
ing Motif 2 and/or Motif 3 (Figure 3). Although the num-
ber of genes that involved in differentiation was <10, and
they, therefore, do not appear on the graph, some intesti-
nal specific differentiation markers, such as lysozyme and
defensins have Motif 3, which is the inverted repeat of the
SOX9 consensus sequence. Despite similarities in the signal-
ing pathways of Motif 1 and Motif 2 and/or 3, the genes in
each group differ with regard to motif. For example, genes
with Motif 1 in Molecular Mechanisms of Cancer pathway
include MAPK1, BRAF, SMAD2, FZD5, FZD8, NOTCH1
and LRP1, whereas genes with Motif 2 and/or Motif3 in the
same pathway include LRP5, LRP6, MDM2, CTNND1,
SMAD3, SMAD4 and SMAD7.
SOX9 and NF-Y bind to the target genes on CCAAT and
form a complex in the nuclei of colorectal cancer cells
The overlapping SOX9 and NF-Y binding sites suggested a
possible direct association between SOX9 and NF-Y in the
chromatin. To test whether SOX9 and NF-Y interact in the
nuclei of colorectal cancer cells, we performed in situ PLA
on HT29 and HCT116 cells. In situ PLA results in high con-
centration of fluorescence only if two proteins are in close
proximity (<40 nm) that indicates protein to protein inter-
action. In situ PLA using anti-SOX9 and anti-NF-YA an-
tibodies showed positive signals in the nuclei of HCT116
(Figure 4A) and HT29 (Supplementary Figure S7) cells, in-
dicating that SOX9 and NF-Y likely form a protein com-
plex.
To determine whether CCAAT is necessary for SOX9
and NF-YA binding to the target genes, we performed
biotin-mediated pull down assay using human wild-type
TOP2A oligo (TOP2A WT) and the mutated TOP2A oligo
(TOP2A M). There are four ATTGG sequences on the hu-
man TOP2A promoter (−221 to +37 bp), one of which is lo-
cated in the center of SOX9 peak obtained from our ChIP-
seq analysis (−106 to −102 bp) (Figure 4B). For the mu-
tated TOP2A oligo, a mutation by 1 bp was made in the
CCAAT to CCAAA in this location. Both SOX9 and NF-
YA bind to wild-type Topo2A promoter, and the mutation
in CCAAT resulted in a significant reduction of both SOX9
and NF-YA binding in vitro (Figure 4C). This confirmed
that SOX9 and NF-Y both require CCAAT to bind to their
target genes. This was further demonstrated by overexpres-
sion of wild-type and mutated TOP2A plasmids, followed
by ChIP-qPCR, showing that 1-bp mutation of CCAAT
reduced both SOX9 and NF-YA binding to TOP2A pro-
moter (Figure 4D). This mutation also reduced the pro-
moter activity of TOP2A (Supplementary Figure S8). To
test whether or not SOX9 directly binds to DNA through
CCAAT motif without NF-Y, we performed EMSA as-
say using recombinant human SOX9 proteins (Figure 4D).
While recombinant SOX9 clearly bound to RASSF3 (Mo-
tif 3 sequence), it did not bind to TOP2A (Motif 1) pro-
moter sequences (Figure 4E). Prior to this experiment, we
confirmed SOX9 binding to both TOP2A and RASSF3 by
ChIP-qPCR using HT-29 (Figure 4F). In addition, HMG
DNA binding domain did not affect SOX9 binding to the
promoters of CCNB1, CDK1 or TOP2A (Supplementary
Figure S9C). Taken together, these results strongly sug-
gest that SOX9 requires NF-Y to bind to the target DNA
through CCAAT.
To further identify the SOX9 domain responsible for
binding to NF-Y, we transfected HCT116 cells with expres-
sion constructs encoding FLAG-tagged wild-type SOX9
(FLAG-WT SOX9); C-terminus-deleted SOX9, carrying
303 amino acids from the N-terminus (FLAG-SOX9–303
C); and HMG domain-deleted SOX9 fused with a nu-
clear localization signal (NLS) at the C-terminus (FLAG-
SOX9 HMG-NLS) (Figure 5A). FLAG-SOX9 HMG-
NLS was generated to compensate for the lack of an NLS
in HMG-deleted SOX9. We first confirmed by western anal-
ysis that each FLAG-tagged protein was expressed (Sup-
plementary Figure S9A), and, immunofluorescence anal-
ysis with anti-FLAG antibody, that the fused extra NLS
enabled SOX9 to translocate into the nucleus (Supple-
mentary Figure S9B) in HCT 116 cells. In situ PLA us-
ing anti-FLAG and anti NF-YA antibodies was then per-
formed on HCT116 cells transfected with constructs encod-
ing the three SOX9 variants. As shown in Figure 5, neither
HMG domain-deleted SOX9 nor C terminus deleted SOX9
formed protein complex with NF-Y, whereas Flag-SOX9
HMG-NLS did. Taken together, our data show that the
C-terminus of SOX9 is required for interaction with NF-Y
in the nucleus (Figure 5B).
NF-Y recruits SOX9 to CCAAT promoters whereas SOX9 is
necessary for transactivation of target genes by NF-Y
NF-Y binding to the CCAAT motifs plays a role in the
opening of target promoter chromatin and facilitates the
recruitment of many cofactors to modulate transcriptional
activity (27,28). To determine whether NF-Y also medi-
ates SOX9 recruitment to the CCAAT boxes of target pro-
moters, we carried out siRNA-mediated knockdown of NF-
YA in HCT116 cells followed by SOX9 ChIP analysis (Fig-
ure 6A). NF-YA knockdown led to a significant decrease
in SOX9 affinity to the promoters of CCNB1 and CDK1
(Figure 6B). This observation suggested that NF-Y recruits
SOX9 to the target promoters. As expected, upon NF-YA
inactivation, expression of both CCNB1 and CDK1 was sig-
nificantly downregulated (Figure 6D). Next, to further in-
vestigate the functional aspect of SOX9 occupancy on these
genes, we knocked down SOX9 in HCT116 cells and mea-
sured NF-YA occupancy, as well as expression levels of the
same target genes (Figure 6A). SOX9 knockdown led to
enhanced affinity of NF-YA binding to the CCNB1 and
CDK1 promoters (Figure 6C). Although one might expect
upregulated expression of NF-Y targets with enhanced NF-
YA binding, expression of both CCNB1 and CDK1 was sig-
nificantly downregulated in SOX9 knockdown cells (Figure
6D). Taken together, these data support the conclusion that
SOX9 is recruited by NF-Y to the promoters of some key
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Figure 3. Pathway analysis of ChIP-Seq-identified SOX9 target genes. SOX9 target genes identified based on ChIP-seq were classified into two groups
based on motif and pathway analysis was performed using IPA software. The top 20 pathways (P < 0.05) ranked by number of genes are presented. Black
bars represent pathways unique to each group.
cell cycle regulatory genes, and that SOX9 is required for
the NF-Y transactivation of these genes.
DISCUSSION
SOX9 has been shown to be critical for cell differentiation
in diverse tissues. Recent ChIP-seq analyses as well as ChIP-
on-chip studies in SOX9 expressing tissues have revealed
many tissue specific SOX9 transcriptional targets. However,
there has not been a report of genome-wide ChIP analysis in
intestinal or there have been few reports identifying SOX9
targets in intestinal epithelium or colorectal cancer cells.
Applying the motif discovery tool MEME to SOX9 ChIP-
seq peaks in HT29 cells, we identified a de novo function of
SOX9, as a cofactor of NF-Y complex through CCAAT,
in addition to its function as a transcription factor through
its known consensus binding sequences, A/TA/TCAAA/TG.
Furthermore, SOX9 binding through CCAAT at promot-
ers is selective to some of the NF-Y binding sites, while
SOX9 itself does not directly bind to target DNA (Supple-
mentary Figure S6). As is the case with many other tran-
scription factors, cofactors of SOX9 have been identified
and shown to be required for precise activation and inac-
tivation of some genes. Those cofactors include exportin 4
(Exp4) (29), steroidogenic factor 1 (SF-1) (30), p300 (31),
Smad3 (32) and PGC-1 (33). In any case, however, SOX9-
dependent transactivation of target genes has been shown to
be mediated by recognizing a specific heptameric DNA se-
quence A/TA/TCAAA/TG through its HMG-box domain.
Our data obtained using human colorectal cancer cells show
that some cell cycle regulatory genes exhibit enriched SOX9
binding to the CCAAT motif, and that those SOX9 en-
riched sites overlap precisely with NF-Y binding peaks in
the proximal promoters. Those genes lack the traditional
binding sequence A/TA/TCAAA/TG within the peak se-
quences. Further, our mutagenesis analyses as well as in
vitro binding assays confirmed CCAAT as the interaction
sequences of SOX9 and NF-Y complexes. Our data showed
that SOX9 does not require its DNA binding domain and
that SOX9 binding on the target genes are NF-Y dependent.
This indicates that SOX9 binding is through NF-Ys on
CCAAT and that SOX9 does not directly bind to CCAAT.
There have been four SOX9 ChIP data reported (21–
23,34), but none of them indicated SOX9 association with
NF-Y on CCAAT. The potential reason includes that two
reports were based on SOX9 ChIP-on-chip with limited
genes placed on the chips (21,22). Two SOX9 ChIP-seq
analyses were also performed on less proliferative tissues,
hair follicle stem cell niches (23) and chondrocytes (34). In
the normal physiology of less proliferative tissue, the affin-
ity of SOX9 binding to CCAAT may be significantly lower
than those to the consensus sequences A/TA/TCAAA/TG
and, therefore, may not be significant. However, it could be
the case that this might be a unique feature of SOX9, ei-
ther tissue specific or context specific. In order to determine
whether SOX9 interaction with NF-Y could be limited to
cancer cells, and not in normal intestinal epithelium, SOX9
ChIP-seq on normal intestinal epithelial cells should be per-
formed.
New finding of SOX9 affinity to CCAAT could also be
associated with the previously reported differential roles of
SOX9 expressed at high and low levels (6). At a high expres-
sion level, SOX9 may bind through all three motifs, Motif 1,
2 and 3, which occur in differentiation marker genes, as well
as other genes that lead to reduced proliferation, whereas at
a low expression level, SOX9 may bind predominantly to
CCAAT motif genes that have relatively higher affinity for
SOX9. In fact, in our ChIP-seq assays, SOX9 enrichment
was observed on some Paneth cell differentiation markers,
such as lysozyme and defensins, suggesting that SOX9 plays
a role in Paneth cell differentiation through the classical mo-
tif, Motif 2 and/or 3. This is consistent with previous studies
in which SOX9 is shown to play a crucial role as a transac-
tivator in differentiation, such as in the outer root sheath
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Figure 4. SOX9 and NF-YA likely form a protein complex. (A) SOX9/NF-YA interaction demonstrated by in situ PLA in HCT116 cells. Red signal indi-
cates interaction of SOX9 and NF-YA. Nuclei were counterstained with DAPI. (B) The sequence of partial TOP2A promoter (−221 to + 37 bp) containing
the center of SOX9 and NF-YA peaks. The center of the peak sequences of SOX9 and NF-YA enriched region, ATTGG (−106 to −102 bp), is marked
by a box. Biotin labeled wild-type TOP2A oligo (WT TOP2A) and the mutated TOP2A (MTOP2A) by 1 bp were synthesized as following sequences, re-
spectively. WT TOP2A: TCCCGCCTCCCTAACCTGATTGGTTTATTCAAACAAACC, MTOP2A: TCCCGCCTCCCTAACCTGTTTGGTTTATT
CAAACAAACC. (C) The biotin-mediated pull down assay showed that SOX9 and NF-YA in HCT116 nuclear extracts bind to biotin labeled wild-type
TOP2A oligo, but 1-bp mutation of CCAAT resulted in a significant reduction of both SOX9 and NF-YA binding. (D) pGL3-WT TOP2A and pGL3-M
TOP2A plasmids were transfected into HCT116 cells, followed by ChIP-qPCR using anti-SOX9 and anti-NF-YA antibodies 48 h post-transfection. A total
of 1-bp mutation of CCAAT reduced the SOX9 and NF-YA binding to TOP2A promoter. (E) EMSA (Figure 4E, left) was performed with biotin-labeled
oligonucleotides for TOP2A (TOP2A bio-F: 5′- biotin-TCCCGCCTCCCTAACCTGATTGGTTTATTCAAACAAACC) and RASSF3 (RASSF3 bio-F:
5′-biotin-ATGACAAGGTCTTTTTGAAGTCACCTGGAATGCTCCCTTT). Both sequences contain the SOX9 peak center obtained from our ChIP-
seq. Recombinant human SOX9 protein directly binds to RASSF3, but not TOP2A. western blot (Figure 4E, right) was performed on the same membrane
used for EMSA to detect recombinant human SOX9 protein. (F) SOX9 and NF-YA ChIP-qPCR analysis showed that SOX9 binds to both TOP2A and
RASSF3 (Motif 3), while NF-YA binds only to TOP2A, but not to RASSF3.
of the hair follicle and in chondrocytes (21,23). Based on
our ChIP-seq analysis, as in other tissues, SOX9 is likely in-
volved in cell differentiation through its consensus binding
sequences.
NF-Y, a ubiquitously expressed heterotrimeric complex
in which NF-YA is the DNA-binding subunit, has been
shown to be a key regulator in cell cycle progression, par-
ticularly at G2/M phase (10,11,35–40). NF-YA has been
shown to be critical for development and cell proliferation
in embryo (25), as well as in adult tissues such as liver (41)
and hematopoietic stem cells (35). As activation of cell cy-
cle regulatory genes by NF-Y has been demonstrated in
various studies, in which NF-Y binding to DNA was in-
hibited either by the expression of the dominant negative
NF-Y subunit or by inactivation of the NF-Y gene (36,42).
Inhibition of DNA binding by NF-Y leads to growth ar-
rest at multiple phases of the cell cycle and the in vivo sig-
nificance of NF-Y was evidenced by NF-YA knockout in
mice, which resulted in early embryonic lethality (25). Re-
cent studies demonstrated the role of NF-Y in stem cell pro-
gression and maintenance, whereas expression is downreg-
ulated during differentiation. However, NF-Y is still active
in differentiated neuronal cells and conditional deletion of
NF-YA in mouse brain induces progressive neurodegenera-
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Figure 5. SOX9 C terminus is responsible for the interaction with NF-YA. (A) Schematic representation of structures of human wild-type and mutant
SOX9 expressed from indicated constructs. DIM: dimerization domain; HMG domain: the DNA-binding domain; K2 and TA: transactivation domains;
PQA: proline-, glutamine- and alanine-rich domain; NLS: nuclear localization sequence. (B) In situ PLA using anti-FLAG and anti-NF-YA antibodies in
HCT116 cells transfected with FLAG-tagged mutant SOX9 constructs depicted in (A). Nuclei were counterstained with DAPI.
tion (43), indicating the crucial role of NF-Y also in post-
mitotic differentiated cells. The roles of NF-Y as an essen-
tial regulator of the pluripotent state in human embryonic
stem cells (ESCs) and cell specification was recently demon-
strated, whereby NF-Y promotes chromatin accessibility of
cell type-specific transcription factors (26). In light of this
report, an interesting future direction is to reveal whether
or not SOX9 may also play a role by binding with NF-Y to
its non-traditional, cell type-specific enhancers in colorec-
tal cancer cells. And this can be done only by performing
NF-Y ChIP-seq using colorectal cancer cells. SOX9 is es-
tablished as being expressed in the proliferative compart-
ment in the intestinal epithelium, where terminally differ-
entiated Paneth cells and quiescent stem cells reside, which
express high expression of SOX9. Whether SOX9 may be
involved in NF-Y target gene regulation in normal intesti-
nal mucosal cells or whether the interaction of SOX9 and
NF-Y is entirely specific to the context of cancer should be
also addressed in a future study.
Our in situ PLA results indicated that SOX9 and NF-Y
comprise a protein complex in the nucleus. ChIP analysis of
NF-Y knockdown cells strongly suggest that NF-Y is nec-
essary for SOX9 binding to the CCAAT sites. This obser-
vation is consistent with the roles of NF-Y, in that histone-
fold domain protein NF-Y pre-sets the promoter architec-
ture that allows other regulatory proteins access (11). On
the other hand, SOX9 knockdown cells showed decreased
expression of NF-Y target genes, indicating that SOX9 is
critical for NF-Y mediated transactivation of these genes.
Taken together, the data show that SOX9 binds to some cell
cycle regulatory genes as a cofactor of NF-Y through the
CCAAT motif and facilitates NF-Y mediated transactiva-





















































































Figure 6. Both SOX9 and NF-Y are required for transcriptional regulation of target genes. (A) siRNA-mediated NF-YA and SOX9 knockdown in HCT116
cells were confirmed by western analysis. (B) SOX9 ChIP-qPCR analysis showed that both NF-YA knockdown cells and SOX9 knockdown cells resulted
in decreased binding affinity of SOX9 to CCNB1 and CDK1 promoters compared to the cells treated with control siRNA (Ctrl). (C) NF-YA ChIP-qPCR
analysis showed that decreased NF-YA expression resulted in reduction of NF-YA binding affinity to CCNB1 and CDK1, however, SOX9 knockdown
enhanced NF-YA binding affinity to these genes. (D) In NF-YA knockdown cells, expression of the corresponding mRNAs was downregulated. Upon
SOX9 knockdown, although NF-YA binding affinity was enhanced, expression of the corresponding mRNAs was downregulated. *P < 0.05, **P < 0.01,
***P < 0.001.
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tion. In SOX9 depleted cells, although NF-Y target cell cy-
cle genes exhibited downregulation, the cells did not show
significant cell cycle arrest. This is perhaps due to the pres-
ence of many other SOX9 target genes that regulate prolif-
eration rate directly or indirectly, the expression of which is
also altered upon SOX9 inactivation. For example, insulin-
like growth factor (IGF)-binding protein 4 (IGFBP-4), an
inhibitor of the IGF/IGF receptor pathway, is a direct tran-
scriptional target of SOX9, whose expression is significantly
downregulated upon inactivation of SOX9 (19).
SOX9 binds to an inverted repeat of a heptameric se-
quence, and this dimeric binding is necessary for SOX9-
dependent transactivation of downstream genes, at least in
some tissues including cartilages (44). For example, SOX9
dimerization mutants have been identified in some cam-
pomelic dysplasia patients, suggesting the importance of
the repetition of the sequence (24). Our ChIP-seq data sug-
gested that some of the genes with high affinity for SOX9
contained inverted repeats of putative sequences (Motif 3);
however, such repeats were also observed in many of the
peak sequences of Motif 2 genes, allowing spacers of 2–14
bp. We hypothesize that dimerization of SOX9 is likely also
required for transactivation of some genes in colorectal can-
cer cells. However, functional assays of each gene are needed
to confirm the mechanism in detail.
SOX9 has also been shown to be indispensable for stem
cell maintenance in some tissues, such as hair follicle, biliary
and pancreatic ductal epithelium and mammary epithelium
(23,29,44). Our ChIP-seq analysis showed enriched SOX9
binding to some intestinal stem cell (ISC) marker genes such
as BMI1, Lrig1 and Lgr5, also suggesting a potential role
of SOX9 for ISC regulation. SOX9 consensus sequences are
identifiable within the peak sequences of each of these genes.
A recent study demonstrated the significance of cell type
specific NF-Y regulation of master ESC transcription fac-
tor expression through distal enhancer binding (26,30). Our
ChIP-seq data showed enrichment of SOX9 binding to pro-
moters of some of the major ISC markers, including BMI1,
Lrig1 and Lgr5. Neither CCAAT boxes nor peaks overlap-
ping with NF-Y ChIP-seq peaks were identified, but SOX9
consensus sequences were observed within those peaks. We
speculate that SOX9 may also be involved in stem cell main-
tenance in the intestinal epithelium. However, SOX9 is not
likely to be involved in the NF-Y-mediated stem cell regu-
lation complexes in the distal enhancer (26).
Although, SOX9 has been reported to inhibit or sustain
cell proliferation in different cell types, on the other hand,
SOX9 is expressed in most human colorectal cancers as well
as in human colorectal cancer cell lines. Our finding of acti-
vation of proliferative genes through NF-Y, therefore, gives
an insight into the oncogenic aspect of SOX9 and helps
to explain why anti-oncogenic protein, SOX9 is highly ex-
pressed in some cancers including most colorectal cancer
cells.
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